A recent FDA Advisory Committee vote could allow researchers to use continuous glucose monitoring (CGM) systems in place of traditional methods, providing “a myriad of customized data,” says Quintiles.
Metabolex, has received its first European patent for metaglidasen
(MBX-102), the company's lead drug candidate for treating type 2
diabetes, insulin resistance, impaired glucose tolerance and
Generex has registered a new patent in the US that covers broad
claims for the delivery of macromolecules via the buccal cavity of
the mouth, further safeguarding its RapidMist drug delivery
technology which it uses to spray insulin...
Alantos Pharmaceuticals has initiated a Phase I trial for its lead
compound for diabetes, a disease that commands a global market
estimated at $11bn (€8.6bn) and is expected to grow by more than 50
per cent by the end of the decade.
The insulin market is set to explode over the next five years as
uptake of insulin therapy is likely to increase with sufferers
benefiting from heightened awareness and knowledge as well as the
influx of affordable, innovative product...
Researchers are developing breakthrough diabetes drugs that use
modified forms of a naturally occurring molecule produced by the
body. The approach characterises the major investments by the
biopharmaceutical industry to develop and...
According to a new report, the global diabetic population is set to
double by 2030, with treatments currently falling way short of
medical needs. The focus falls on impending products offering novel
therapies to diabetics and for...
The limited efficacy of existing diabetes therapies is set to pose
the main challenge for the European diabetes diagnostics markets as
the uptake and adoption for new innovative techniques determining
the future of this burgeoning...
The latest research included in the proceedings of the annual
scientific meeting of the American Diabetes Association (ADA) means
that diabetic treatments and other therapies for the disease
feature strongly in DrugResearcher's...
Living Cell Technologies (LCT) are set to put a major dent in the
market for diabetic treatments after they announced the retrieval
of live, insulin-producing cells, from a patient, in a transplant
that did not require the use of...
The lead agent in a new class of drugs for the treatment of
diabetes - Novartis' LAF-237 - seems to improve glucose control
without the weight gain associated with other orally-active drugs
for this common disease, reports Phil...
Researchers in Finland and the US have identified a gene that
predisposes people to one of the most common causes of coronary
heart disease, raising the hope that it could represent a new
target for drug treatment.